Loading…
← CockpitCompetitor Analysis › 002365.SZ Qianjiang Yongan Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Qianjiang Yongan Pharmaceutical Co., Ltd. Class A002365.SZCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Specialty
Momentum strong 70
Mkt cap
$500M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$26.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+8.0 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥11.41
1D-1.3%
1W-7.4%
1M-3.5%
3M-15.0%
6M-12.6%
YTD-23.5%
1Y-33.7%
ATR %4.2%
52w lowhigh37.0% off high

What Qianjiang Yongan Pharmaceutical does

Employees: 912

Qianjiang Yongan Pharmaceutical at a glance

Size Qianjiang Yongan Pharmaceutical (002365.SZ) is a China Materials company (Chemicals: Specialty) with a market value of $500M, the 3706th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.41 on 18 Nov 2026.

Performance Over six months the shares fell 12.6%, against -22.3% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 45.4% over the last twelve months (peer median +5.2%); the operating margin is 11.2% (peer median 0.7%).

Valuation It trades at 2.2× enterprise value to sales against a peer median of 1.4× (8th most expensive of 21).

Capital Return on invested capital runs 8.0 points above its cost of capital (5.0% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026002365.SZ 90Peer median 78
Six months, rebased to 100: Qianjiang Yongan Pharmaceutical against the median of its 20 peers (local-currency closes).

Qianjiang Yongan Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.15BCN¥779MCN¥835MCN¥969MCN¥1.46B
Revenue growth—-7%-14%-33%—
Gross profitCN¥390MCN¥117MCN¥150MCN¥236MCN¥462M
EBITDAn/aCN¥109MCN¥152MCN¥159MCN¥293M
Net incomeCN¥111MCN¥22.5MCN¥61.8M-CN¥12.3MCN¥140M
Free cash flow-CN¥32.7MCN¥105MCN¥23.0MCN¥124MCN¥265M
Capital expenditureCN¥178MCN¥62.3MCN¥118MCN¥121MCN¥149M
Total debtCN¥345,182CN¥9.96MCN¥46.0MCN¥47.3MCN¥47.2M

Quarterly statements and history in the cockpit →

Qianjiang Yongan Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%3007980368306030510008221312000731688196600527001358300481171160072760311360327607460024692103300522002986002365.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Qianjiang Yongan Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%2×4×6×30079803683060305100082213120007316881966005270013582553300481171160072760311360327607460024692103300522002986002365.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Qianjiang Yongan Pharmaceutical is the large dot.

Qianjiang Yongan Pharmaceutical competitors and peer comparison

How Qianjiang Yongan Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Qianjiang Yongan Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002365.SZPeer medianRank in peer set
1-month return-3.5%-13.9%4th highest of 21
6-month return-12.6%-22.3%8th highest of 20
Distance from 52-week high-37.0%-48.2%8th highest of 21
Revenue growth (TTM)+45.4%+5.2%2nd highest of 21
Operating margin11.2%0.7%2nd highest of 21
EV / Sales2.2×1.4×8th most expensive of 21
ROIC minus cost of capital+8.0 pp-4.4 pphighest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Qianjiang Yongan Pharmaceutical 002365.SZChina$500M-13%+45%11%2.2×n/an/a
Jiangsu Jinji Industrial 300798.SZChina$498M-32%+28%0%2.5×n/an/a
Soulbrain 036830.KSSouth Korea$502M-44%+17%-3%1.3×n/an/a
Guangzhou Lushan New Materials 603051.SSChina$502M-13%-5%0%1.8×28.0%+8.5%
Shandong Haihua 000822.SZChina$497M-30%-10%-33%1.3×n/an/a
Grand Pacific Petrochemical 1312.TWTaiwan$505M+10%+41%-12%1.4×n/an/a
Sichuan Meifeng Chemical Industry 000731.SZChina$494M-7%-13%-6%0.5×n/an/a
Longyan Zhuoyue New Energy 688196.SSChina$509M-43%-6%0%1.3×n/an/a
Jiangsu Jiangnan High Polymer Fiber 600527.SSChina$512M-31%+5%2%4.4×8.9%-14.6%
Shaoxing Xingxin New Material 001358.SZChina$513M-12%-8%9%6.0×n/an/a
Beijing Shougang LanzaTech Technology 2553.HKHong Kong$514Mn/a0%-45%8.0×n/an/a
Puyang Huicheng Electronic Material 300481.SZChina$518M-21%+11%9%2.0×n/an/a
Everlight Chemical Industrial 1711.TWTaiwan$518M-38%+7%1%2.3×n/an/a
Shandong Lubei Chemical 600727.SSChina$520M-22%+6%7%0.9×n/an/a
Jinneng Science & Technology 603113.SSChina$521M-23%+6%-4%0.5×n/an/a
Jiangsu Hengxing New Material Technology 603276.SSChina$527M-3%+29%8%2.9×15.9%+15.2%
Lee & Man Chemical 0746.HKHong Kong$473M-2%+3%18%1.1×-7.5%+3.9%
Shandong Sunway Chemical 002469.SZChina$529M-24%-19%3%1.4×n/an/a
TSRC 2103.TWTaiwan$529M+5%+10%7%0.6×n/an/a
Suzhou Sunmun Technology 300522.SZChina$530M-17%-5%-2%5.4×n/an/a
Guangdong Yussen Energy Technology 002986.SZChina$531M-30%+57%2%0.6×-5.5%+27.8%

Questions

Which companies are Qianjiang Yongan Pharmaceutical's closest peers?
The cockpit's peer set: Jiangsu Jinji Industrial (300798.SZ), Soulbrain (036830.KS), Guangzhou Lushan New Materials (603051.SS), Shandong Haihua (000822.SZ), Grand Pacific Petrochemical (1312.TW), Sichuan Meifeng Chemical Industry (000731.SZ), Longyan Zhuoyue New Energy (688196.SS), Jiangsu Jiangnan High Polymer Fiber (600527.SS).
Is Qianjiang Yongan Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 2.2× against a peer median of 1.4×, 8th most expensive of 21 in its peer set.
How has Qianjiang Yongan Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -12.6% against -22.3% for the median peer; over one year -33.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.